Telix Pharmaceuticals Ltd has released a press release.
Illuccix Granted Use Authorisation in Brazil
Filed with ASX ·
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call6ix hasn’t read this filing yet.
Telix Pharmaceuticals Limited on 6ix
Earlier from Telix Pharmaceuticals
- Investor Presentation - November 2021
- Australian TGA Approves Illuccix for Prostate Cancer Imaging
- Activities Report and App 4C - September 2021 quarter
- IPAX-1 Presentation at Congress of Neurological Surgeons
- $12.1M R&D Tax Refund, Overseas Finding Increased to $139M
Later from Telix Pharmaceuticals
- NUCLIBER - Distribution Agreement for Illuccix in Spain
- Illuccix EU Regulatory Submission Progress Update
- FDA Approves Telix Prostate Cancer Imaging Product Illuccix
- Targeted Alpha Therapy for Bladder Cancer 1st patient dosed
- Telix completes $175M placement and launches $25M SPP
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals